Literature DB >> 7290125

The natural break points for primary-tumor thickness in clinical Stage I melanoma.

C L Day, R A Lew, M C Mihm, M N Harris, A W Kopf, A J Sober, T B Fitzpatrick.   

Abstract

Entities:  

Mesh:

Year:  1981        PMID: 7290125     DOI: 10.1056/NEJM198111053051916

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  14 in total

1.  A proposal for staging malignant melanoma.

Authors:  C Kuehnl-Petzold; H Wiebelt; H Berger; G Wagner
Journal:  Arch Dermatol Res       Date:  1983       Impact factor: 3.017

2.  Clinical significance of occult metastatic melanoma in sentinel lymph nodes and other high-risk factors based on long-term follow-up.

Authors:  Stanley P L Leong; Mohammed Kashani-Sabet; Renee A Desmond; Robert P Kim; Dennis H Nguyen; Kensho Iwanaga; Patrick A Treseler; Robert E Allen; Eugene T Morita; Yuting Zhang; Richard W Sagebiel; Seng-Jaw Soong
Journal:  World J Surg       Date:  2005-06       Impact factor: 3.352

3.  Thin (less than or equal to 1 mm) melanomas of the extremities are biologically favorable lesions not influenced by regression.

Authors:  H J Wanebo; P H Cooper; R W Hagar
Journal:  Ann Surg       Date:  1985-04       Impact factor: 12.969

4.  Prognostic factors for melanoma patients with lesions 0.76 - 1.69 mm in thickness. An appraisal of "thin" level IV lesions.

Authors:  C L Day; M C Mihm; A J Sober; M N Harris; A W Kopf; T B Fitzpatrick; R A Lew; T J Harrist; F M Golomb; A Postel; P Hennessey; S L Gumport; J W Raker; R A Malt; A B Cosimi; W C Wood; D F Roses; F Gorstein; D Rigel; R J Friedman; M M Mintzis
Journal:  Ann Surg       Date:  1982-01       Impact factor: 12.969

5.  Malignant melanomas of the oral cavity: heterogeneity of pathological and clinical features.

Authors:  K Ohashi; T Kasuga; N Tanaka; S Enomoto; J Horiuchi; N Okada
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992

6.  A multivariate analysis of prognostic factors for melanoma patients with lesions greater than or equal to 3.65 mm in thickness. The importance of revealing alternative Cox models.

Authors:  C L Day; R A Lew; M C Mihm; A J Sober; M N Harris; A W Kopf; T B Fitzpatrick; T J Harrist; F M Golomb; A Postel; P Hennessey; S L Gumport; J W Raker; R A Malt; A B Cosimi; W C Wood; D F Roses; F Gorstein; D Rigel; R J Friedman; M M Mintzis; R W Grier
Journal:  Ann Surg       Date:  1982-01       Impact factor: 12.969

7.  Prognostic factors for patients with clinical stage I melanoma of intermediate thickness (1.51 - 3.39 mm). A conceptual model for tumor growth and metastasis.

Authors:  C L Day; M C Mihm; R A Lew; M N Harris; A W Kopf; T B Fitzpatrick; T J Harrist; F M Golomb; A Postel; P Hennessey; S L Gumport; J W Raker; R A Malt; A B Cosimi; W C Wood; D F Roses; F Gorstein; D Rigel; R J Friedman; M M Mintzis; A J Sober
Journal:  Ann Surg       Date:  1982-01       Impact factor: 12.969

8.  Prognostic role of antibody reactivity to melanoma.

Authors:  D R Vlock; R DerSimonian; J M Kirkwood
Journal:  J Clin Invest       Date:  1986-04       Impact factor: 14.808

9.  Treatment with coumarin to prevent or delay recurrence of malignant melanoma.

Authors:  R D Thornes; L Daly; G Lynch; B Breslin; H Browne; H Y Browne; T Corrigan; P Daly; G Edwards; E Gaffney
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

10.  "Mitogenicity"-the latest and mosthilarious episode in the slapstick comedy of melanoma management.

Authors:  Wolfgang Weyers
Journal:  Dermatol Pract Concept       Date:  2012-07-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.